5%环孢菌素霜对银屑病合并代谢综合征患者血清IL-17及IL-18水平的影响
|
摘要
目的:探讨5%环孢菌素霜对银屑病合并代谢综合征患者外周血IL-17、IL-18水平及PASI评分的影响。方法:选择我院收治的寻常型银屑病合并代谢综合症患者68例,分为实验组和对照组。对照组予以复方甘草酸苷和卡泊三醇治疗,实验组在此基础上加用制备好的5%环孢菌素霜,观察并比较两组患者治疗前后外周血IL-17及IL-18水平的变化情况以及血压、空腹血糖、血脂及PASI评分结果。结果:与治疗前比较,两组患者治疗后IL-17及IL-18水平、血压、FPG、TG及PASI评分均显著降低,而HDL-C明显升高,差异均具有统计学意义(P<0.05);与对照组比较,实验组治疗后IL-17及IL-18水平、血压、FPG、TG及PASI评分较低,而HDL-C较高,差异均具有统计学意义(P<0.05)。结论:5%环孢菌素霜辅助治疗可调节银屑病合并代谢综合征患者外周血IL-17、IL-18水平,降低其PASI评分,改善患者机体代谢紊乱状态,对银屑病合并代谢综合症有显著临床疗效。
Objective: To investigate the effect of 5% cyclosporin cream on the changes of IL-18, IL-17 levels in peripheral blood and PASI of psoriasis patients combined with metabolic syndrome. Methods: 68 cases of psoriasis patients with metabolic syndrome who were treated in our hospital were selected and randomly divided into the control group and the experimental group. The patients in control group were treated with the compound licorice injection, while the patients in experimental group were treated with the 5% cyclosporin on the basis of control group. Then the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI scores in both groups were observed and compared before and after the treatment. Results: Compared with before treatment, the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI scores decreased in both groups after the treatment(P<0.05). Compared with the control group, the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI score were lower in the experimental group after the treatment(P<0.05). Conclusion: 5% cyclosporin cream could regulate the levels of IL-18 and IL-17 in peripheral blood of patients with psoriasis combined with metabolic syndrome, reduce the PASI score and improve the metabolic disorder.
Objective: To investigate the effect of 5% cyclosporin cream on the changes of IL-18, IL-17 levels in peripheral blood and PASI of psoriasis patients combined with metabolic syndrome. Methods: 68 cases of psoriasis patients with metabolic syndrome who were treated in our hospital were selected and randomly divided into the control group and the experimental group. The patients in control group were treated with the compound licorice injection, while the patients in experimental group were treated with the 5% cyclosporin on the basis of control group. Then the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI scores in both groups were observed and compared before and after the treatment. Results: Compared with before treatment, the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI scores decreased in both groups after the treatment(P<0.05). Compared with the control group, the levels of IL-17 and IL-18 in serum, blood pressure, FPG, TG and the PASI score were lower in the experimental group after the treatment(P<0.05). Conclusion: 5% cyclosporin cream could regulate the levels of IL-18 and IL-17 in peripheral blood of patients with psoriasis combined with metabolic syndrome, reduce the PASI score and improve the metabolic disorder.
引文
[1]Rich P,Sigurgeirsson B,Thaci D,et al.Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis:a randomized,double-blind,placebo-controlled,phase II regimen-finding study[J].British Journal of Dermatology,2013,168(2):402-411
[2]Rosa,Parisi,Deborah P M,et al.Global epidemiology of psoriasis:a systematic review of incidence and prevalence[J].Journal of Investigative Dermatology,2013,133(2):377-385
[3]Papp K A,Langley R G,Sigurgeirsson B,et al.Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis:a randomized,double-blind,placebo-controlled phase II dose-ranging study[J].Br J Dermatol,2013,168(2):412-421
[4]Wang Y T,Tsai P C,Liao Y C,et al.Circulating micro RNAs have a sex-specific association with metabolic syndrome[J].Journal of Biomedical Science,2013,20(1):471-477
[5]Tzellos T,Kyrgidis A,Zouboulis C C.Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis:a meta-analysis of randomized controlled trials[J].Journal of the European Academy of Dermatology&Venereology,2013,27(5):622-627
[6]Burmester GR,Panaccione R,Gordon KB,et al.Adalimumab:long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis,juvenile idiopathic arthritis,ankylosing spondylitis,psoriatic arthritis,psoriasis and Crohn's disease[J].Annals of the Rheumatic Diseases,2013,72(4):517-524
[7]Armstrong A W,Harskamp C T,Armstrong E J.Psoriasis and metabolic syndrome:A systematic review and meta-analysis of observational studies[J].Journal of the American Academy of Dermatology,2013,68(4):654-662
[8]Martin D A,Towne J E,Kricorian G,et al.The emerging role of IL-17in the pathogenesis of psoriasis:preclinical and clinical findings[J].Journal of Investigative Dermatology,2013,133(1):17-26
[9]Armstrong A W,Harskamp C T,Armstrong E J.The association between psoriasis and hypertension:a systematic review and meta-analysis of observational studies[J].Journal of Hypertension,2013,31(3):433-443
[10]Navarro R,Vilarrasa E,Herranz P,et al.Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C:a retrospective,multicentre study in a clinical setting[J].Br J Dermatol,2013,168(3):609-616
[11]Ma C,Harskamp C T,Armstrong E J,et al.The association between psoriasis and dyslipidaemia:a systematic review[J].British Journal of Dermatology,2013,168(3):486-495
[12]Daudén E,Casta09eda S,Suárez C,et al.Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis[J].J Eur Acad Dermatol Venereol,2013,27(11):1387-1404
[13]Ahlehoff O,Skov L,Gislason G,et al.Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs:a Danish real-world cohort study[J].Journal of Internal Medicine,2013,273(2):197-204
[14]Ortonne J P,Paul C,Berardesca E,et al.A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis[J].British Journal of Dermatology,2013,168(5):1080-1087
[15]Yiu KH,Yeung CK,Zhao CT,et al.Prevalence and extent of subclinical atherosclerosis in patients with psoriasis[J].Journal of Internal Medicine,2013,273(3):273-282
[16]Thorneloe R J,Bundy C,Griffiths C E M,et al.Adherence to medication in patients with psoriasis:a systematic literature review[J].British Journal of Dermatology,2013,168(1):20-31
[17]Naldi L,Conti A,Cazzaniga S,et al.Diet and physical exercise in psoriasis:a randomized controlled trial[J].Br J Dermatol,2014,170(3):634-642
[18]Chiu HY,Chen CH,Wu MS,et al.The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C[J].British Journal of Dermatology,2013,169(6):1295-1303
[19]Sivamani R K,Goodarzi H,Garcia M S,et al.Biologic Therapies In The Treatment Of Psoriasis:A Comprehensive Evidence-Based Basic Science And Clinical Review And A Practical Guide To Tuberculosis Monitoring[J].Clinical Reviews in Allergy&Immunology,2013,44(2):121-140
[20]Kirkham B W,Kavanaugh A,Reich K.Interleukin-17A:a unique pathway in immune-mediated diseases:psoriasis,psoriatic arthritis and rheumatoid arthritis[J].Immunology,2014,141(2):133-142
[2]Rosa,Parisi,Deborah P M,et al.Global epidemiology of psoriasis:a systematic review of incidence and prevalence[J].Journal of Investigative Dermatology,2013,133(2):377-385
[3]Papp K A,Langley R G,Sigurgeirsson B,et al.Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis:a randomized,double-blind,placebo-controlled phase II dose-ranging study[J].Br J Dermatol,2013,168(2):412-421
[4]Wang Y T,Tsai P C,Liao Y C,et al.Circulating micro RNAs have a sex-specific association with metabolic syndrome[J].Journal of Biomedical Science,2013,20(1):471-477
[5]Tzellos T,Kyrgidis A,Zouboulis C C.Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis:a meta-analysis of randomized controlled trials[J].Journal of the European Academy of Dermatology&Venereology,2013,27(5):622-627
[6]Burmester GR,Panaccione R,Gordon KB,et al.Adalimumab:long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis,juvenile idiopathic arthritis,ankylosing spondylitis,psoriatic arthritis,psoriasis and Crohn's disease[J].Annals of the Rheumatic Diseases,2013,72(4):517-524
[7]Armstrong A W,Harskamp C T,Armstrong E J.Psoriasis and metabolic syndrome:A systematic review and meta-analysis of observational studies[J].Journal of the American Academy of Dermatology,2013,68(4):654-662
[8]Martin D A,Towne J E,Kricorian G,et al.The emerging role of IL-17in the pathogenesis of psoriasis:preclinical and clinical findings[J].Journal of Investigative Dermatology,2013,133(1):17-26
[9]Armstrong A W,Harskamp C T,Armstrong E J.The association between psoriasis and hypertension:a systematic review and meta-analysis of observational studies[J].Journal of Hypertension,2013,31(3):433-443
[10]Navarro R,Vilarrasa E,Herranz P,et al.Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C:a retrospective,multicentre study in a clinical setting[J].Br J Dermatol,2013,168(3):609-616
[11]Ma C,Harskamp C T,Armstrong E J,et al.The association between psoriasis and dyslipidaemia:a systematic review[J].British Journal of Dermatology,2013,168(3):486-495
[12]Daudén E,Casta09eda S,Suárez C,et al.Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis[J].J Eur Acad Dermatol Venereol,2013,27(11):1387-1404
[13]Ahlehoff O,Skov L,Gislason G,et al.Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs:a Danish real-world cohort study[J].Journal of Internal Medicine,2013,273(2):197-204
[14]Ortonne J P,Paul C,Berardesca E,et al.A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis[J].British Journal of Dermatology,2013,168(5):1080-1087
[15]Yiu KH,Yeung CK,Zhao CT,et al.Prevalence and extent of subclinical atherosclerosis in patients with psoriasis[J].Journal of Internal Medicine,2013,273(3):273-282
[16]Thorneloe R J,Bundy C,Griffiths C E M,et al.Adherence to medication in patients with psoriasis:a systematic literature review[J].British Journal of Dermatology,2013,168(1):20-31
[17]Naldi L,Conti A,Cazzaniga S,et al.Diet and physical exercise in psoriasis:a randomized controlled trial[J].Br J Dermatol,2014,170(3):634-642
[18]Chiu HY,Chen CH,Wu MS,et al.The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C[J].British Journal of Dermatology,2013,169(6):1295-1303
[19]Sivamani R K,Goodarzi H,Garcia M S,et al.Biologic Therapies In The Treatment Of Psoriasis:A Comprehensive Evidence-Based Basic Science And Clinical Review And A Practical Guide To Tuberculosis Monitoring[J].Clinical Reviews in Allergy&Immunology,2013,44(2):121-140
[20]Kirkham B W,Kavanaugh A,Reich K.Interleukin-17A:a unique pathway in immune-mediated diseases:psoriasis,psoriatic arthritis and rheumatoid arthritis[J].Immunology,2014,141(2):133-142